Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 2022.

IF 1.9 4区医学 Q3 ONCOLOGY

Clinical Medicine Insights-Oncology Pub Date : 2024-02-06 eCollection Date: 2024-01-01 DOI:10.1177/11795549241227413

David J Benjamin, Arash Rezazadeh Kalebasty

引用次数: 0

查看原文本刊更多论文

2004 年至 2022 年转移性前列腺癌获批药物的特征和生存获益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Medicine Insights-Oncology Medicine-Oncology

CiteScore

2.40

自引率

4.50%

发文量

审稿时长

8 weeks

期刊介绍： Clinical Medicine Insights: Oncology is an international, peer-reviewed, open access journal that focuses on all aspects of cancer research and treatment, in addition to related genetic, pathophysiological and epidemiological topics. Of particular but not exclusive importance are molecular biology, clinical interventions, controlled trials, therapeutics, pharmacology and drug delivery, and techniques of cancer surgery. The journal welcomes unsolicited article proposals.